Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2 Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of the Selective SYK Inhibitor Lanraplenib (LANRA) in Combination With the FLT3 Inhibitor Gilteritinib, in Patients With FLT3-mutated Relapsed or Refractory AML

NCT05028751 is registered in ClinicalTrials.gov with Kronos Bio as lead sponsor.

NCT NCT05028751
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05028751 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2 Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of the Selective SYK Inhibitor Lanraplenib (LANRA) in Combination With the FLT3 Inhibitor Gilteritinib, in Patients With FLT3-mutated Relapsed or Refractory AML
Lead sponsor
Kronos Bio
Phase
Phase 1/2
Overall status
Terminated
Start date
August 5, 2022
Completion date
April 9, 2024
Enrollment
24 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, refractory acute myeloid leukemia, relapsed acute myeloid leukemia